Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16380
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTai, Geneieve-
dc.contributor.authorCorben, Louise A-
dc.contributor.authorYiu, Eppie M-
dc.contributor.authorDelatycki, Martin B-
dc.date2016-09-28-
dc.date.accessioned2016-10-23T23:21:14Z-
dc.date.available2016-10-23T23:21:14Z-
dc.date.issued2017-07-
dc.identifier.citationActa Neurologica Scandinavica 2017; 136(1): 41-46en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16380-
dc.description.abstractOBJECTIVES: The Medical Outcomes Study 36 item Short-Form Health Survey (SF-36) is one of the most commonly used patient reported outcome measure. This study aimed to examine the relationship between SF-36 version 2 (SF-36V2) summary scores and Friedreich ataxia (FRDA) clinical characteristics, and to investigate the responsiveness of the scale, in comparison with the Friedreich Ataxia Rating Scale (FARS), over 1, 2 and 3 years. MATERIALS AND METHODS: Descriptive statistics were used to examine the characteristics of the cohort at baseline and years 1, 2 and 3. Correlations between FRDA clinical characteristics and SF-36V2 summary scores were reported. Responsiveness was measured using paired t tests. RESULTS: We found significant correlations between the physical component summary (PCS) of the SF-36V2 and various FRDA clinical parameters but none for the mental component summary. No significant changes in the SF-36V2 were seen over 1 or 2 years; however, PCS scores at Year 3 were significantly lower than at baseline (-3.3, SD [7.6], P=.01). FARS scores were found to be significantly greater at Years 1, 2 and 3 when compared to baseline. CONCLUSIONS: Our findings suggest that despite physical decline, individuals with FRDA have relatively stable mental well-being. This study demonstrates that the SF-36V2 is unlikely to be a useful tool for identifying clinical change in FRDA therapeutic trials.en_US
dc.subjectFriedreich ataxiaen_US
dc.subjectHealth statusen_US
dc.subjectRating Scalesen_US
dc.subjectSF-36en_US
dc.titleA longitudinal study of the SF-36 version 2 in Friedreich ataxiaen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleActa Neurologica Scandinavica en_US
dc.identifier.affiliationBruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Psychological Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Paediatrics, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Occupational Therapy, Monash Health, Clayton, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Neurology, Royal Children's Hospital, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Clinical Genetics, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27679455en_US
dc.identifier.doi10.1111/ane.12693en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherDelatycki, Martin B
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptClinical Genetics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.